Literature DB >> 2048217

5-Hydroxytryptamine: a chameleon in the heart.

P R Saxena1, C M Villalón.   

Abstract

5-HT has profound effects on cardiac rate and force in a variety of animal species, including humans. The main initial response to 5-HT is a short-lasting bradycardia, mediated via a Bezold-Jarisch-like reflex, and initiated by stimulation of 5-HT3 receptors present on cardiac vagal afferents. Once this bradycardia is suppressed, 5-HT induces cardiac stimulation which, true to its chameleonic nature described here by Pramod Saxena and Carlos Villalón, is mediated by different mechanisms and receptors in different species. In several species, including humans, coronary vasodilatation is mediated by 5-HT1-like receptors, while both 5-HT1-like and 5-HT2 receptors mediate vasoconstriction. This knowledge may lead to a better assessment of the possible role of 5-HT in cardiovascular pathologies and to the development of selective 5-HT receptor agonists and antagonists for therapeutic usefulness in heart failure, coronary vasospasm and to avoid potential cardiac side-effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2048217     DOI: 10.1016/0165-6147(91)90556-8

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  22 in total

Review 1.  Serotonin and blood pressure regulation.

Authors:  Stephanie W Watts; Shaun F Morrison; Robert Patrick Davis; Susan M Barman
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

2.  Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle.

Authors:  U Jahnel; J Rupp; R Ertl; H Nawrath
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

3.  Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Authors:  Araceli Sánchez-Lopez; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

4.  Operational characteristics of the 5-HT1-like receptors mediating external carotid vasoconstriction in vagosympathectomized dogs. Close resemblance to the 5-HT1D receptor subtype.

Authors:  C M Villalón; A Sánchez-López; D Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

5.  The atypical 5-HT2 receptor mediating tachycardia in pithed rats: pharmacological correlation with the 5-HT2A receptor subtype.

Authors:  David Centurión; Mario I Ortiz; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

6.  Cardiovascular effects of cisapride and prucalopride on human 5-HT4 receptors in transgenic mice.

Authors:  Nicolas Keller; Stefan Dhein; Joachim Neumann; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-09       Impact factor: 3.000

7.  Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial.

Authors:  F B Cakir; O Yapar; C Canpolat; F Akalin; S G Berrak
Journal:  Support Care Cancer       Date:  2012-01-13       Impact factor: 3.603

8.  Suppression of reperfusion-induced arrhythmias with combined administration of 5-HT2 and thromboxane A2 antagonists.

Authors:  L A Shaw; S J Coker
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

9.  Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B and 5-HT1D subtypes.

Authors:  Araceli Sánchez-López; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-12-12       Impact factor: 3.000

10.  L-type calcium channel activity in human atrial myocytes as influenced by 5-HT.

Authors:  U Jahnel; H Nawrath; J Rupp; R Ochi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.